To explore 6-month and 12-month secukinumab effectiveness in patients with axial spondyloarthritis (axSpA) overall, as well as across (1) number of previous biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), (2) time since diagnosis and (3) different European registries.

Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration / Michelsen, Brigitte; Lindström, Ulf; Codreanu, Catalin; Ciurea, Adrian; Zavada, Jakub; Loft, Anne Gitte; Pombo-Suarez, Manuel; Onen, Fatos; Kvien, Tore K; Rotar, Ziga; Santos, Maria Jose; Iannone, Florenzo; Hokkanen, Anna-Mari; Gudbjornsson, Bjorn; Askling, Johan; Ionescu, Ruxandra; Nissen, Michael J; Pavelka, Karel; Sanchez-Piedra, Carlos; Akar, Servet; Sexton, Joseph; Tomsic, Matija; Santos, Helena; Sebastiani, Marco; Österlund, Jenny; Geirsson, Arni Jon; Macfarlane, Gary; van der Horst-Bruinsma, Irene; Georgiadis, Stylianos; Brahe, Cecilie Heegaard; Ørnbjerg, Lykke Midtbøll; Hetland, Merete Lund; Østergaard, Mikkel. - In: RMD OPEN. - ISSN 2056-5933. - 6:3(2020), pp. e001280-e001280. [10.1136/rmdopen-2020-001280]

Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration

Sebastiani, Marco;
2020

Abstract

To explore 6-month and 12-month secukinumab effectiveness in patients with axial spondyloarthritis (axSpA) overall, as well as across (1) number of previous biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), (2) time since diagnosis and (3) different European registries.
2020
6
3
e001280
e001280
Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration / Michelsen, Brigitte; Lindström, Ulf; Codreanu, Catalin; Ciurea, Adrian; Zavada, Jakub; Loft, Anne Gitte; Pombo-Suarez, Manuel; Onen, Fatos; Kvien, Tore K; Rotar, Ziga; Santos, Maria Jose; Iannone, Florenzo; Hokkanen, Anna-Mari; Gudbjornsson, Bjorn; Askling, Johan; Ionescu, Ruxandra; Nissen, Michael J; Pavelka, Karel; Sanchez-Piedra, Carlos; Akar, Servet; Sexton, Joseph; Tomsic, Matija; Santos, Helena; Sebastiani, Marco; Österlund, Jenny; Geirsson, Arni Jon; Macfarlane, Gary; van der Horst-Bruinsma, Irene; Georgiadis, Stylianos; Brahe, Cecilie Heegaard; Ørnbjerg, Lykke Midtbøll; Hetland, Merete Lund; Østergaard, Mikkel. - In: RMD OPEN. - ISSN 2056-5933. - 6:3(2020), pp. e001280-e001280. [10.1136/rmdopen-2020-001280]
Michelsen, Brigitte; Lindström, Ulf; Codreanu, Catalin; Ciurea, Adrian; Zavada, Jakub; Loft, Anne Gitte; Pombo-Suarez, Manuel; Onen, Fatos; Kvien, Tor...espandi
File in questo prodotto:
File Dimensione Formato  
2020 michelsen Drug retention.pdf

Open access

Descrizione: Main document
Tipologia: Versione pubblicata dall'editore
Dimensione 1.09 MB
Formato Adobe PDF
1.09 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1210694
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 39
  • ???jsp.display-item.citation.isi??? ND
social impact